The Importance of Vascular Endothelial Growth Factor as a Marker of Angiogenesis and Lymphangiogenesis in Non-small Cell Lung Cancer

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10-30.10.3322/canjclin.55.1.1015661684Search in Google Scholar

2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592.10.1093/annonc/mdl49817287242Search in Google Scholar

3. Frank C Detterbeck, Sandra Zelman Lewis, Rebecca Diekemper, Doreen Addrizzo Harris, Michael Alberts. Diagnosis and Management of lung Cancer, 3rd ed. American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(5_suppl):7S-37S.10.1378/chest.12-237723649434Search in Google Scholar

4. Howard BA, Furumai R, Campa MJ, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 2005;65:8853–8860.10.1158/0008-5472.CAN-05-121916204056Search in Google Scholar

5. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.10.1056/NEJMoa06188417167137Search in Google Scholar

6. Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology. 2008;68:183–196.10.1016/j.critrevonc.2008.05.00218606548Search in Google Scholar

7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182—1186.10.1056/NEJM1971111828521084938153Search in Google Scholar

8. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;41:143-158.10.1016/j.lungcan.2005.09.00516360975Search in Google Scholar

9. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphaticmetastasis. J ExpMed. 2005;201:1089–1099.10.1084/jem.20041896221313215809353Search in Google Scholar

10. Kawai H, Minamiya Y, Ito M, et al. VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer 2008;59:41–47.10.1016/j.lungcan.2007.08.00117868952Search in Google Scholar

11. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19:5598–5605.10.1038/sj.onc.1203855Search in Google Scholar

12. O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000;82:1427—1432.10.1054/bjoc.1999.1129Search in Google Scholar

13. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Invading edge vs. inner (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol. 2000;192:140—149.10.1002/1096-9896(2000)9999:9999<::AID-PATH693>3.0.CO;2-RSearch in Google Scholar

14. Takizawa H, Kondo K, Fujino H, et al. The balance of VEGF-C and VEGFR-3mRNA is a predictor of lymph nodemetastasis in non-small cell lung cancer. Br J Cancer. 2006;95:75–79.10.1038/sj.bjc.6603209Search in Google Scholar

15. Choi JH, Kim HC, Lim HY, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001;33(2–3):171–179.10.1016/S0169-5002(01)00200-8Search in Google Scholar

16. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3(6):861–865.Search in Google Scholar

17. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851—858.10.1016/0006-291X(89)92678-8Search in Google Scholar

18. De Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989—991.10.1126/science.1312256Search in Google Scholar

19. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835—846.10.1016/0092-8674(93)90573-9Search in Google Scholar

20. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer. 2006;94:1355–1360.10.1038/sj.bjc.6603120Search in Google Scholar

21. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, et al. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol. 2006;209:34—43.10.1002/path.1943Search in Google Scholar

22. Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol. 2006;18:151–155.10.1097/01.cco.0000208788.99570.0eSearch in Google Scholar

23. Seto T, HigashiyamaM, Funai H, Imamura F, Uematsu K, Seki N, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53:91–96.10.1016/j.lungcan.2006.02.009Search in Google Scholar

24. Decaussin M, Sartelet H, Robert C, MoroD, Claraz C, Brambilla C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGFR1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999;188:369–377.10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-XSearch in Google Scholar

25. Wang S, Liu H, Ren L, Pan Y, Zhang Y. Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia. 2008; 10:399–407.10.1593/neo.07613Search in Google Scholar

26. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 2003;63:4801–4804.Search in Google Scholar

27. Feng Y, Hu J, Ma J, et al. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways, Eur J Cancer. 2011;47:2353-2363.Search in Google Scholar

28. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996;73:931–934.10.1038/bjc.1996.166Search in Google Scholar

29. Farhat FS, Tfayli A, Fakhruddin N, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer, Clinical Reviews in Oncology/Hematology. 2012,84:149-160.10.1016/j.critrevonc.2012.02.012Search in Google Scholar

30. Kadota K, Huang CL, Liu D, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057–1067.10.1016/j.ejca.2008.03.012Search in Google Scholar

31. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33:125–132.10.1016/S0169-5002(01)00195-7Search in Google Scholar

32. Pajares MJ, Agorreta J, Larrayoz M, et al. Expression of tumorderived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012;30:1129–1136.10.1200/JCO.2011.37.4231Search in Google Scholar

33. Delmotte P, Martin B, Paesmans M, et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir. 2002;19:577–584.Search in Google Scholar

34. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4:1094–1103.10.1097/JTO.0b013e3181a97e31Search in Google Scholar

35. Nakashima T, Huang CL, Liu D, Kameyama K, Masuya D, Ueno M, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit.2004;10:BR157–165.Search in Google Scholar

36. Dziadziuszko R, Chyczewski L, Jassem E, Jassem J. Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)—a preliminary report. Folia HistochemCytobiol. 2001;39(Suppl. 2):100–101.Search in Google Scholar

37. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296:1883–1886.10.1126/science.1071420Search in Google Scholar

38. Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Munoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 2009;115:1701–171210.1002/cncr.24193Search in Google Scholar

39. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal. 2000;12:123–133.10.1016/S0898-6568(99)00076-5Search in Google Scholar

40. Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008;68:7828–7837.10.1158/0008-5472.CAN-08-1488Search in Google Scholar

41. Donnem T, Al-Shibli K, Al-Saad C, Delghandi MP, Busund LT, Bremnes RM. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: Inverse correlation between expression in tumor and stromal cells, Lung Cancer. 2009;63:277-283.Search in Google Scholar

42. Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan S, Tastepe I. Vascular Endothelial Growth Factor Immunostaining Correlates with Postoperative elapse and Survival in Non-Small Cell Lung Cancer, Arch Res med. 2007;38:764-768.Search in Google Scholar

43. Volm M, Koomägi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997;74:64–68.10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-ISearch in Google Scholar

44. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg. 1998;115:1007–1014.10.1016/S0022-5223(98)70398-8Search in Google Scholar

45. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer. 2005;115:545–555.10.1002/ijc.20898Search in Google Scholar

46. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–623.10.1093/clinchem/47.4.617Search in Google Scholar

47. Bonnesen B, Pappot H, Holmstav J, Guldhammer Skov B. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis, Lung Cancer. 2009,66:314-318.10.1016/j.lungcan.2009.02.013Search in Google Scholar

48. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33(2–3):125–132.10.1016/S0169-5002(01)00195-7Search in Google Scholar

49. Hormbrey E, Gillespie P, Turner K, et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis. 2002;19:651–663.Search in Google Scholar

50. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond). 1998;94:395–404.10.1042/cs0940395Search in Google Scholar

51. Sorreensen S, Fohlin H, Lindgren A, et al. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy, Eur J Cancer. 2013;49:115-120.Search in Google Scholar

52. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer. BMC Cancer. 2009;9:421.10.1186/1471-2407-9-421Search in Google Scholar

53. Ohta Y, Watanabe Y, Murakami S, et al. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer. 1997;76(8):1041–1045.10.1038/bjc.1997.505Search in Google Scholar

54. Brattstrom D, Bergqvist M, Hesselius P, et al. Elevatedpreoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer. 2002;37(1):57–63.10.1016/S0169-5002(02)00027-2Search in Google Scholar

55. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178–187.10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7Search in Google Scholar

56. Lin-Hsu I., Wu-Chou S., Jing-Jou Y., Jia-Ming C., Wu-Wei L. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:371-376.10.1016/j.lungcan.2008.12.007Search in Google Scholar

57. Grove CS, Lee YC. Vascular endothelial growth factor: the keymediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8:294–301.10.1097/00063198-200207000-00009Search in Google Scholar

58. Nathanson SD. Insights into the mechanisms of lymph node metastases. Cancer. 2003;98:413—423.10.1002/cncr.11464Search in Google Scholar

59. Cao Y. Emerging mechanisms of tumor lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005;5:1—9.10.1038/nrc1693Search in Google Scholar

60. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastases. Nat Rev Cancer. 2002;2:573—583.10.1038/nrc863Search in Google Scholar

61. Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, et al. Enhancement of pleural dissemination and lymph node metastases of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004;45:325—337.10.1016/j.lungcan.2004.02.02115301873Search in Google Scholar

62. Saintigny P., Kambouchner M., Li M., et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: Concurrent expression in cancer cells from primary tumour and metastatic lymph node, Lung Cancer. 2007;58:205-213.Search in Google Scholar

63. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65:4739-4746.10.1158/0008-5472.CAN-04-457615930292Search in Google Scholar

64. Achen MG, Williams RA, Baldwin ME, Lai P, Roufail S, Alitalo K, et al. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors. 2002;20:99-107.10.1080/0897719029003196912148568Search in Google Scholar

65. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–436.10.1038/nrc136915170445Search in Google Scholar

66. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191.10.1200/JCO.2004.11.02215169807Search in Google Scholar

67. Reck M, Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer, Lung Cancer. 2009;63:1-9.Search in Google Scholar

68. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.2.2008. Available at: http://www.nccn.org/professionals/physiciangls/PDF/nscl.pdf.Search in Google Scholar